Your browser is no longer supported. Please, upgrade your browser.
AKRO Akero Therapeutics, Inc. weekly Stock Chart
AKRO [NASD]
Akero Therapeutics, Inc.
Index- P/E- EPS (ttm)-2.09 Insider Own9.51% Shs Outstand28.60M Perf Week-11.09%
Market Cap1.09B Forward P/E- EPS next Y-3.66 Insider Trans28.42% Shs Float17.92M Perf Month-7.43%
Income-59.30M PEG- EPS next Q-0.65 Inst Own73.30% Short Float5.32% Perf Quarter27.48%
Sales- P/S- EPS this Y4.50% Inst Trans1.09% Short Ratio2.72 Perf Half Y89.56%
Book/sh3.62 P/B8.88 EPS next Y-41.90% ROA-44.80% Target Price62.14 Perf Year67.80%
Cash/sh3.03 P/C10.61 EPS next 5Y- ROE-48.00% 52W Range10.78 - 41.16 Perf YTD44.85%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-21.89% Beta-
Dividend %- Quick Ratio10.90 Sales past 5Y- Gross Margin- 52W Low198.24% ATR1.82
Employees13 Current Ratio10.90 Sales Q/Q- Oper. Margin- RSI (14)39.60 Volatility6.18% 5.59%
OptionableYes Debt/Eq0.00 EPS Q/Q-112.00% Profit Margin- Rel Volume0.33 Prev Close31.95
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume350.68K Price32.15
Recom1.70 SMA20-5.27% SMA50-8.22% SMA20023.76% Volume116,163 Change0.63%
Sep-10-20Initiated Morgan Stanley Overweight $70
Jul-20-20Reiterated H.C. Wainwright Buy $45 → $62
Jul-07-20Initiated Chardan Capital Markets Buy $79
Jul-01-20Reiterated H.C. Wainwright Buy $33 → $45
Mar-02-20Initiated H.C. Wainwright Buy $33
Feb-10-20Initiated Canaccord Genuity Buy $36
Jul-15-19Initiated ROTH Capital Buy $34
Jul-15-19Initiated JP Morgan Overweight $28
Jul-15-19Initiated Jefferies Buy $28
Jul-15-19Initiated Evercore ISI Outperform $35
Sep-24-20 07:30AM  
Sep-16-20 04:25PM  
Sep-13-20 08:48AM  
Sep-09-20 04:05PM  
Aug-12-20 04:05PM  
Jul-23-20 11:02AM  
Jul-21-20 11:00AM  
Jul-10-20 04:05PM  
Jul-07-20 08:15PM  
Jul-06-20 07:00AM  
Jul-02-20 08:21AM  
Jul-01-20 09:03AM  
08:12AM  
Jun-30-20 04:05PM  
Jun-29-20 04:05PM  
Jun-27-20 09:28PM  
Jun-17-20 08:00AM  
Jun-10-20 12:00PM  
11:30AM  
10:30AM  
08:00AM  
Jun-04-20 07:08AM  
May-27-20 09:24AM  
May-26-20 04:05PM  
May-22-20 11:30AM  
May-13-20 04:05PM  
May-08-20 12:00PM  
Apr-06-20 12:00PM  
08:58AM  
Mar-31-20 08:26AM  
06:00AM  
Mar-30-20 04:05PM  
Mar-16-20 11:19AM  
07:31AM  
Feb-14-20 11:55AM  
Jan-27-20 06:05AM  
Jan-13-20 08:00AM  
Jan-08-20 04:05PM  
Dec-19-19 05:51PM  
Dec-16-19 04:05PM  
Dec-14-19 07:22PM  
Nov-13-19 04:01PM  
Nov-12-19 07:00AM  
Nov-04-19 08:00AM  
Oct-31-19 02:07PM  
Sep-19-19 06:54AM  
Sep-04-19 07:00AM  
Aug-12-19 07:00AM  
Jul-09-19 10:07AM  
Jul-03-19 07:31AM  
Jul-02-19 04:05PM  
Jun-24-19 04:05PM  
Jun-20-19 11:44AM  
Jun-19-19 09:20PM  
Jun-18-19 12:10PM  
Jun-17-19 10:07AM  
Akero Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development and commercialization of treatments for serious metabolic diseases. Its lead product candidate is AKR-001, which is in Phase IIa clinical trial for the treatment of nonalcoholic steatohepatitis disease.The company was formerly known as Pippin Pharmaceuticals, Inc. and changed its name to Akero Therapeutics, Inc. in May 2018. Akero Therapeutics, Inc. was founded in 2017 and is headquartered in South San Francisco, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Apple Tree Partners IV, L.P.10% OwnerJul 10Buy36.00415,00014,940,0005,830,203Jul 14 04:46 PM
Harrison Seth LoringDirectorJul 10Buy36.00415,00014,940,0005,830,203Jul 14 04:45 PM
venBio Global Strategic Fund I10% OwnerJul 06Sale33.834,603155,7213,033,552Jul 06 07:00 PM
venBio Global Strategic Fund I10% OwnerJul 02Sale33.633,800127,8053,038,155Jul 06 07:00 PM
venBio Global Strategic Fund I10% OwnerJul 01Sale34.45108,0643,723,0103,041,955Jul 06 07:00 PM